MS treatment with stem cell transplant in the Netherlands
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have relapsing-remitting MS and have been approved for this stem cell treatment in the Netherlands.
- You cannot have any allergies to the medications used in the transplant.
- You must not have other serious health problems that would make the transplant unsafe.
- You cannot have severe depression, active drug or alcohol addiction, or certain active infections.
- You must not have active cancer or a history of cancer (except for certain skin cancers or cervical cancer in situ).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at biomarkers (biological signs in your blood) in people with immune-mediated neurological diseases. It compares those getting a stem cell transplant to those on high-efficacy MS treatments to understand how these therapies work.
This trial uses your own blood stem cells to reboot your immune system, which may help stop multiple sclerosis attacks and slow disability. It is for people with active MS that has not responded well to other treatments.
This early-phase study tests a stem cell transplant procedure for people with multiple sclerosis whose usual MS medicines have not worked or can’t be tolerated. The goal is to see if this approach can help control MS activity and progression, while checking for safety.
This trial tests a new way to treat primary progressive multiple sclerosis (PPMS) using a stem cell transplant from a healthy donor. The goal is to see if this approach can stop or slow the disease and improve quality of life.
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
This Phase 1/2 trial studies whether donated umbilical cord stem cells are safe and can improve multiple sclerosis. It aims to see if the treatment is workable for people who still have active MS despite standard therapies.
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.